1.

Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and
selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778.

2.

Chakravarty EF, Bush TM, Manzi S, et al. Prevalence of adult systemic lupus erythematosus
in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis
Rheum 2007; 56:2092.

3.

Pons-Estel GJ, Alarcn GS, Scofield L, et al. Understanding the epidemiology and
progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39:257.

4.

Uramoto KM, Michet CJ Jr, Thumboo J, et al. Trends in the incidence and mortality of
systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42:46.

5.

Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a

comparison of worldwide disease burden. Lupus 2006; 15:308.

6.

Rus V, Maury EE, Hochberg MC. The epidemiology of systemic lupus erythematosus. In:
Dubois' Lupus Erythematosus, Wallace DJ, Hahn BH (Eds), Lippincott Williams and Wilkins,
Philadelphia 2002.

7.

Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples.
Semin Arthritis Rheum 1999; 28:368.

8.

Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol
2002; 16:847.

9.

Hochberg MC. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 19701977. Arthritis Rheum 1985; 28:80.

10.

Serdula MK, Rhoads GG. Frequency of systemic lupus erythematosus in different ethnic
groups in Hawaii. Arthritis Rheum 1979; 22:328.

11.

Symmons DP. Frequency of lupus in people of African origin. Lupus 1995; 4:176.

12.

Hart HH, Grigor RR, Caughey DE. Ethnic difference in the prevalence of systemic lupus
erythematosus. Ann Rheum Dis 1983; 42:529.

13.

Chung SA, Tian C, Taylor KE, et al. European population substructure is associated with
mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus.
Arthritis Rheum 2009; 60:2448.

14.

Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal, environmental, and infectious risk
factors for developing systemic lupus erythematosus. Arthritis Rheum 1998; 41:1714.

15.

Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal
factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007; 56:1251.

16.

Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol
1999; 11:352.

17.

Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone
hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized
trial. Ann Intern Med 2005; 142:953.

18.

Moser KL, Kelly JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic
lupus erythematosus. Genes Immun 2009; 10:373.

19.

Scofield RH, Bruner GR, Namjou B, et al. Klinefelter's syndrome (47,XXY) in male systemic
lupus erythematosus patients: support for the notion of a gene-dose effect from the X
chromosome. Arthritis Rheum 2008; 58:2511.

20.

Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus.
J Immunol 2006; 176:7143.

21.
22.

23.

Lockshin MD. Sex differences in autoimmune disease. Lupus 2006; 15:753.

Rothfield N. Clinical features of systemic lupus erythematosus. In: Textbook of Rheumatology,
Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1981.
Schaller J. Lupus in childhood. Clin Rheum Dis 1982; 8:219.

24.

Ballou SP, Khan MA, Kushner I. Clinical features of systemic lupus erythematosus:
differences related to race and age of onset. Arthritis Rheum 1982; 25:55.

25.

Fernndez M, Alarcn GS, Calvo-Aln J, et al. A multiethnic, multicenter cohort of patients

with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE.
Arthritis Rheum 2007; 57:576.

26.

Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus.

Identification of racial and socioeconomic influences. Arch Intern Med 1990; 150:849.

27.

Reveille JD, Bartolucci A, Alarcn GS. Prognosis in systemic lupus erythematosus. Negative
impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death.
Arthritis Rheum 1990; 33:37.

28.

Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide
for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103.

29.

Callahan LF, Pincus T. Associations between clinical status questionnaire scores and formal
education level in persons with systemic lupus erythematosus. Arthritis Rheum 1990; 33:407.

30.

Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus

erythematosus: role of race and socioeconomic status. Am J Med 1991; 91:345.

31.

Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American
prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and
disease heterogeneity among "Hispanics". Medicine (Baltimore) 2004; 83:1.

32.

Citera G, Wilson WA. Ethnic and geographic perspectives in SLE. Lupus 1993; 2:351.

33.

Johnson AE, Cavalcanti FS, Gordon C, et al. Cross-sectional analysis of the differences
between patients with systemic lupus erythematosus in England, Brazil and Sweden. Lupus
1994; 3:501.

34.

Lu LJ, Wallace DJ, Ishimori ML, et al. Review: Male systemic lupus erythematosus: a review
of sex disparities in this disease. Lupus 2010; 19:119.

35.

Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and
immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working
Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72:113.

36.

Kaufman LD, Gomez-Reino JJ, Heinicke MH, Gorevic PD. Male lupus: retrospective analysis
of the clinical and laboratory features of 52 patients, with a review of the literature. Semin Arthritis
Rheum 1989; 18:189.

37.

Miller MH, Urowitz MB, Gladman DD, Killinger DW. Systemic lupus erythematosus in males.
Medicine (Baltimore) 1983; 62:327.

38.

Ward MM, Studenski S. Systemic lupus erythematosus in men: a multivariate analysis of

gender differences in clinical manifestations. J Rheumatol 1990; 17:220.

39.

Prete PE, Majlessi A, Gilman S, Hamideh F. Systemic lupus erythematosus in men: a

retrospective analysis in a Veterans Administration Healthcare System population. J Clin
Rheumatol 2001; 7:142.

40.

Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic
lupus erythematosus. Arthritis Rheum 1989; 32:1226.

41.

Boddaert J, Huong DL, Amoura Z, et al. Late-onset systemic lupus erythematosus: a personal
series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore)
2004; 83:348.

42.

Lalani S, Pope J, de Leon F, et al. Clinical features and prognosis of late-onset systemic lupus
erythematosus: results from the 1000 faces of lupus study. J Rheumatol 2010; 37:38.

43.

Schur PH. Genetics of systemic lupus erythematosus. Lupus 1995; 4:425.

44.

Wong M, Tsao BP. Current topics in human SLE genetics. Springer Semin Immunopathol
2006; 28:97.

45.

Harley JB, Kelly JA, Kaufman KM. Unraveling the genetics of systemic lupus erythematosus.
Springer Semin Immunopathol 2006; 28:119.

46.

Block SR, Winfield JB, Lockshin MD, et al. Studies of twins with systemic lupus
erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med 1975;
59:533.

47.

Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic

lupus erythematosus. Arthritis Rheum 1992; 35:311.

48.

Arnett FC, Reveille JD, Wilson RW, et al. Systemic lupus erythematosus: current state of the
genetic hypothesis. Semin Arthritis Rheum 1984; 14:24.

49.

Hunnangkul S, Nitsch D, Rhodes B, et al. Familial clustering of non-nuclear autoantibodies

and C3 and C4 complement components in systemic lupus erythematosus. Arthritis Rheum 2008;
58:1116.

50.

Murashima A, Fukazawa T, Hirashima M, et al. Long term prognosis of children born to lupus
patients. Ann Rheum Dis 2004; 63:50.

51.

Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with
C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358:900.

52.

Graham RR, Hom G, Ortmann W, Behrens TW. Review of recent genome-wide association
scans in lupus. J Intern Med 2009; 265:680.

53.

Nath SK, Han S, Kim-Howard X, et al. A nonsynonymous functional variant in integrinalpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 2008;
40:152.

54.

Barcellos LF, May SL, Ramsay PP, et al. High-density SNP screening of the major
histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for
independent susceptibility regions. PLoS Genet 2009; 5:e1000696.

55.

International MHC and Autoimmunity Genetics Network, Rioux JD, Goyette P, et al. Mapping
of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc
Natl Acad Sci U S A 2009; 106:18680.

56.

Kariuki SN, Kirou KA, MacDermott EJ, et al. Cutting edge: autoimmune disease risk variant of
STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009;
182:34.

57.

Niewold TB, Kelly JA, Flesch MH, et al. Association of the IRF5 risk haplotype with high
serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008;
58:2481.

58.

Kariuki SN, Crow MK, Niewold TB. The PTPN22 C1858T polymorphism is associated with
skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor
alpha levels in patients with lupus. Arthritis Rheum 2008; 58:2818.

59.

Abelson AK, Delgado-Vega AM, Kozyrev SV, et al. STAT4 associates with systemic lupus
erythematosus through two independent effects that correlate with gene expression and act
additively with IRF5 to increase risk. Ann Rheum Dis 2009; 68:1746.

60.

Lazarus M, Hajeer AH, Turner D, et al. Genetic variation in the interleukin 10 gene promoter
and systemic lupus erythematosus. J Rheumatol 1997; 24:2314.

61.

Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to
glomerulonephritis in rats and humans. Nature 2006; 439:851.

62.

Yang Y, Chung EK, Wu YL, et al. Gene copy-number variation and associated polymorphisms
of complement component C4 in human systemic lupus erythematosus (SLE): low copy number
is a risk factor for and high copy number is a protective factor against SLE susceptibility in
European Americans. Am J Hum Genet 2007; 80:1037.

63.

Hawn TR, Wu H, Grossman JM, et al. A stop codon polymorphism of Toll-like receptor 5 is
associated with resistance to systemic lupus erythematosus. Proc Natl Acad Sci U S A 2005;
102:10593.

64.

Orr V, Tsai SJ, Rueda B, et al. A loss-of-function variant of PTPN22 is associated with
reduced risk of systemic lupus erythematosus. Hum Mol Genet 2009; 18:569.

65.

Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases. J

Autoimmun 2009; 33:3.

66.

Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I
interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009;
60:1065.

67.

Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J
Autoimmun 2009; 32:189.

68.

Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and
systemic lupus erythematosus. N Engl J Med 2007; 357:977.

69.

Taylor KE, Remmers EF, Lee AT, et al. Specificity of the STAT4 genetic association for severe
disease manifestations of systemic lupus erythematosus. PLoS Genet 2008; 4:e1000084.

70.

Svenungsson E, Gustafsson J, Leonard D, et al. A STAT4 risk allele is associated with

ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus
erythematosus. Ann Rheum Dis 2010; 69:834.

71.

Yin H, Borghi MO, Delgado-Vega AM, et al. Association of STAT4 and BLK, but not BANK1 or
IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 2009; 60:2468.

72.

Lu R, Vidal GS, Kelly JA, et al. Genetic associations of LYN with systemic lupus
erythematosus. Genes Immun 2009; 10:397.

73.

Jnsen A, Gunnarsson I, Gullstrand B, et al. Association between SLE nephritis and

polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford) 2007;
46:1417.

74.

Kyogoku C, Tsuchiya N, Wu H, et al. Association of Fcgamma receptor IIA, but not IIB and
IIIA, polymorphisms with systemic lupus erythematosus: A family-based association study in
Caucasians. Arthritis Rheum 2004; 50:671.

75.

Croker JA, Kimberly RP. Genetics of susceptibility and severity in systemic lupus
erythematosus. Curr Opin Rheumatol 2005; 17:529.

76.

Kim-Howard X, Maiti AK, Anaya JM, et al. ITGAM coding variant (rs1143679) influences the
risk of renal disease, discoid rash and immunological manifestations in patients with systemic
lupus erythematosus with European ancestry. Ann Rheum Dis 2010; 69:1329.

77.

Kariuki SN, Franek BS, Kumar AA, et al. Trait-stratified genome-wide association study
identifies novel and diverse genetic associations with serologic and cytokine phenotypes in
systemic lupus erythematosus. Arthritis Res Ther 2010; 12:R151.

78.

Sestak AL, Nath SK, Sawalha AH, Harley JB. Current status of lupus genetics. Arthritis Res
Ther 2007; 9:210.

79.

McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and metaanalysis. Arthritis Rheum 2003; 48:2100.

80.

Li J, May W, McMurray RW. Pituitary hormones and systemic lupus erythematosus. Arthritis
Rheum 2005; 52:3701.

81.

Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic
lupus erythematosus. N Engl J Med 2005; 353:2550.

82.

Snchez-Guerrero J, Uribe AG, Jimnez-Santana L, et al. A trial of contraceptive methods in

women with systemic lupus erythematosus. N Engl J Med 2005; 353:2539.

83.

Snchez-Guerrero J, Gonzlez-Prez M, Durand-Carbajal M, et al. Menopause hormonal

therapy in women with systemic lupus erythematosus. Arthritis Rheum 2007; 56:3070.

84.

Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal and reproductive risk factors for
development of systemic lupus erythematosus: results of a population-based, case-control study.
Arthritis Rheum 2002; 46:1830.

85.

Ulff-Mller CJ, Jrgensen KT, Pedersen BV, et al. Reproductive factors and risk of systemic
lupus erythematosus: nationwide cohort study in Denmark. J Rheumatol 2009; 36:1903.

86.

Roubinian JR, Talal N, Greenspan JS, et al. Effect of castration and sex hormone treatment
on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med
1978; 147:1568.

87.

Mountz JD, Gause WC, Jonsson R. Murine models for systemic lupus erythematosus and
Sjgren's syndrome. Curr Opin Rheumatol 1991; 3:738.

88.

Subramanian S, Tus K, Li QZ, et al. A Tlr7 translocation accelerates systemic autoimmunity in

murine lupus. Proc Natl Acad Sci U S A 2006; 103:9970.

89.

Pisitkun P, Deane JA, Difilippantonio MJ, et al. Autoreactive B cell responses to RNA-related
antigens due to TLR7 gene duplication. Science 2006; 312:1669.

90.

Berghfer B, Frommer T, Haley G, et al. TLR7 ligands induce higher IFN-alpha production in
females. J Immunol 2006; 177:2088.

91.

Nikpour M, Dempsey AA, Urowitz MB, et al. Association of a gene expression profile from
whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 2008;
67:1069.

92.

Cutolo M, Sulli A, Seriolo B, et al. Estrogens, the immune response and autoimmunity. Clin
Exp Rheumatol 1995; 13:217.

93.

Cohen-Solal JF, Jeganathan V, Grimaldi CM, et al. Sex hormones and SLE: influencing the
fate of autoreactive B cells. Curr Top Microbiol Immunol 2006; 305:67.

94.

Lahita RG. Sex hormones and the immune system--Part 1. Human data. Baillieres Clin
Rheumatol 1990; 4:1.

95.

Suzuki T, Suzuki N, Engleman EG, et al. Low serum levels of dehydroepiandrosterone may
cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus
(SLE). Clin Exp Immunol 1995; 99:251.

96.

Clemens LE, Siiteri PK, Stites DP. Mechanism of immunosuppression of progesterone on

maternal lymphocyte activation during pregnancy. J Immunol 1979; 122:1978.

97.

Buskila D, Sukenik S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Am J

Reprod Immunol 1991; 26:118.

98.

Blanco-Favela F, Quintal-Alvarez G, Leaos-Miranda A. Association between prolactin and

disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol
1999; 26:55.

99.

Weetman AP, Walport MJ. The association of autoimmune thyroiditis with systemic lupus
erythematosus. Br J Rheumatol 1987; 26:359.

100.
Goh KL, Wang F. Thyroid disorders in systemic lupus erythematosus. Ann Rheum Dis 1986;
45:579.
101.
Glck T, Oertel M, Reber T, et al. Altered function of the hypothalamic stress axes in patients
with moderately active systemic lupus erythematosus. I. The hypothalamus-autonomic nervous
system axis. J Rheumatol 2000; 27:903.

102.
McClain MT, Arbuckle MR, Heinlen LD, et al. The prevalence, onset, and clinical significance
of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis
Rheum 2004; 50:1226.
103.

Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85:303.

104.
Theofilopoulos AN. The basis of autoimmunity: Part I. Mechanisms of aberrant selfrecognition. Immunol Today 1995; 16:90.
105.
Hahn BH, Ebling F, Singh RR, et al. Cellular and molecular mechanisms of regulation of
autoantibody production in lupus. Ann N Y Acad Sci 2005; 1051:433.
106.

Elkon K. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7:384.

107.
Klinman DM, Steinberg AD. Inquiry into murine and human lupus. Immunol Rev 1995;
144:157.
108.
Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the
clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526.
109.
Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease. A problem of defective apoptosis.
Arthritis Rheum 1994; 37:1415.
110.
Graham KL, Utz PJ. Sources of autoantigens in systemic lupus erythematosus. Curr Opin
Rheumatol 2005; 17:513.
111.

Muoz LE, Janko C, Grossmayer GE, et al. Remnants of secondarily necrotic cells fuel
inflammation in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1733.

112.
Gerl V, Lischka A, Panne D, et al. Blood dendritic cells in systemic lupus erythematosus
exhibit altered activation state and chemokine receptor function. Ann Rheum Dis 2010; 69:1370.
113.
Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma
cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;
48:1332.
114.
Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease
activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95.
Arthritis Rheum 2008; 58:1762.
115.
Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function
in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579.
116.
Stohl W. Impaired polyclonal T cell cytolytic activity. A possible risk factor for systemic lupus
erythematosus. Arthritis Rheum 1995; 38:506.
117.
Tsokos GC. Lymphocytes, cytokines, inflammation, and immune trafficking. Curr Opin
Rheumatol 1995; 7:376.
118.
Linker-Israeli M, Quismorio FP Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic
lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and
synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990; 33:1216.
119.
Pugh-Bernard AE, Cambier JC. B cell receptor signaling in human systemic lupus
erythematosus. Curr Opin Rheumatol 2006; 18:451.

120.
Krishnan S, Chowdhury B, Tsokos GC. Autoimmunity in systemic lupus erythematosus:
integrating genes and biology. Semin Immunol 2006; 18:230.
121.
Mohan C, Datta SK. Lupus: key pathogenic mechanisms and contributing factors. Clin
Immunol Immunopathol 1995; 77:209.
122.
Prodeus AP, Goerg S, Shen LM, et al. A critical role for complement in maintenance of selftolerance. Immunity 1998; 9:721.
123.
Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in
systemic lupus erythematosus. J Exp Med 2005; 201:703.
124.
Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus: will the
promise be fulfilled? Immunol Rev 2008; 223:156.
125.
Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebocontrolled, dose-ranging study of belimumab in patients with active systemic lupus
erythematosus. Arthritis Rheum 2009; 61:1168.
126.
Navarra SV, Guzmn RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients
with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Lancet 2011; 377:721.
127.

Steinberg AD. Insights into the basis of systemic lupus. J Autoimmun 1995; 8:771.

128.
Tsokos GC. Calcium signaling in systemic lupus erythematosus lymphocytes and its
therapeutic exploitation. Arthritis Rheum 2008; 58:1216.
129.
Abbud Filho M, Pavarino-Bertelli EC, Alvarenga MP, et al. Systemic lupus erythematosus and
microchimerism in autoimmunity. Transplant Proc 2002; 34:2951.
130.
Rnnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus
erythematosus. Arthritis Rheum 2006; 54:408.
131.
Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic
lupus erythematosus blood. J Exp Med 2003; 197:711.
132.
Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced
genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50:3958.
133.
Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature
in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100:2610.
134.
Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene
expression with disease activity and lupus nephritis in patients with systemic lupus
erythematosus. Arthritis Rheum 2006; 54:2951.
135.
Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus.
Lupus 2010; 19:1012.
136.
Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory
factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of
systemic lupus erythematosus. Nat Genet 2006; 38:550.

137.
Nzeusseu Toukap A, Galant C, Theate I, et al. Identification of distinct gene expression
profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007;
56:1579.
138.
Lpez P, Gmez J, Prado C, et al. Influence of functional interleukin 10/tumor necrosis factoralpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with
systemic lupus erythematosus receiving antimalarial treatment. J Rheumatol 2008; 35:1559.
139.
Manzi S, Navratil JS, Ruffing MJ, et al. Measurement of erythrocyte C4d and complement
receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004; 50:3596.
140.
Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr Opin
Rheumatol 2008; 20:538.
141.
Goodnow CC. Immunology. Discriminating microbe from self suffers a double toll. Science
2006; 312:1606.
142.
Papadimitraki ED, Choulaki C, Koutala E, et al. Expansion of toll-like receptor 9-expressing B
cells in active systemic lupus erythematosus: implications for the induction and maintenance of
the autoimmune process. Arthritis Rheum 2006; 54:3601.
143.
Migita K, Miyashita T, Maeda Y, et al. Toll-like receptor expression in lupus peripheral blood
mononuclear cells. J Rheumatol 2007; 34:493.
144.
Nakano S, Morimoto S, Suzuki J, et al. Role of pathogenic auto-antibody production by Tolllike receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 2008;
47:145.
145.
Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs
through cooperation of CD32 and TLR9. J Clin Invest 2005; 115:407.
146.
Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and
clinical disease by Toll-like receptors. Semin Immunol 2007; 19:11.
147.
Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid
activity in lupus. Nature 2010; 465:937.
148.
Li J, Xie H, Wen T, et al. Expression of high mobility group box chromosomal protein 1 and its
modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol
2010; 37:766.
149.

Pisetsky DS. HMGB1: a dangerous player in lupus pathogenesis. J Rheumatol 2010; 37:689.

150.

Via CS, Ha